Related Experiment Video
Updated: May 28, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
Published on: June 24, 2025
Risk Factors for Catheter-Related Thrombosis
Leyla La Cava1, Davide Giustivi2, Arianna Bartoli1
1Internal Medicine, Ospedale Luigi Sacco, Aziende Socio Sanitarie Territoriali (ASST) Fatebenefratelli-Sacco, 20157 Milan, Italy.
Insights
Pharmacological prophylaxis, including anticoagulant and antiplatelet therapy, significantly reduces catheter-related thrombosis (CRT) risk in patients with peripherally inserted central catheters (PICCs) and midline catheters (MCs). PICC use also lowers CRT incidence.
Area of Science:
- Vascular Access Devices
- Thrombosis Research
- Pharmacological Interventions
Background:
- Catheter-related thrombosis (CRT) is a significant complication of peripherally inserted central catheters (PICCs) and midline catheters (MCs), despite adherence to insertion guidelines.
- The efficacy of pharmacological prophylaxis for preventing CRT remains a subject of ongoing debate within the medical community.
Purpose of the Study:
- To evaluate the incidence of CRT in patients undergoing anticoagulant therapy (prophylactic or therapeutic) and antiplatelet therapy.
- To assess the protective effects of these pharmacological interventions against CRT in patients with PICCs and MCs.
Main Methods:
- Retrospective study of 1431 adult patients at a tertiary care hospital (March 2021-May 2023).
- Analysis of confounders including anticoagulation status, antiplatelet therapy, catheter type (PICCs vs. MCs), number of lumens, CRT risk factors, and drug infusion.
- CRT diagnosis via compression ultrasonography in symptomatic patients; statistical analysis using propensity score weighting and logistic regression.
Main Results:
- Peripherally inserted central catheters (PICCs) and therapeutic anticoagulant therapy demonstrated strong protective effects against CRT (OR 0.068 and 0.007, respectively).
- Prophylactic anticoagulant therapy (OR 0.328) and antiplatelet therapy (OR 0.342) also showed significant protective effects.
- No independent association found between CRT and catheter lumens, risk factors, or infusion of irritating drugs.
Conclusions:
- Anticoagulant drugs (prophylactic and therapeutic), antiplatelet therapy, and PICC utilization significantly reduce the risk of catheter-related thrombosis.
- Findings support personalized strategies for CRT prevention.
- A randomized controlled trial is recommended to validate these observations.
Abstract:
Background: Although guidelines emphasize proper insertion techniques and tip positioning, catheter-related thrombosis (CRT) remains a common and clinically significant complication of peripherally inserted central catheters (PICCs) and midline catheters (MCs). In this context, the use of pharmacological prophylaxis is still debated. This study aims to assess the incidence of CRT in patients receiving anticoagulant therapy (therapeutic or prophylactic) and antiplatelet therapy. Methods: This retrospective study was conducted at a tertiary care hospital and included adult patients from March 2021 to May 2023. Six potential confounders were analyzed: anticoagulation status (none, prophylaxis, therapeutic), antiplatelet therapy, tip position (PICCs vs. MCs), number of lumens, CRT risk factors, and drug infusion requiring central access. CRT was diagnosed in symptomatic patients using compression ultrasonography. Propensity score weighting and logistic regression were employed to estimate odds ratios (OR) and average treatment effects. Results: A total of 1431 patients were enrolled. PICCs and therapeutic anticoagulant therapy were highly protective against CRT (OR 0.068 [95% CI 0.013-0.2] and OR 0.007 [95% CI 0.001-0.046], respectively). Prophylactic anticoagulant therapy (OR 0.328 [95% CI 0.200-0.519]) and antiplatelet therapy (OR 0.342 [95% CI 0.182-0.595]) also showed protective effects. At the same time, neither the number of lumens, the presence of risk factors, nor the infusion of irritating drugs was independently associated with CRT. Conclusions: The use of anticoagulant drugs (both prophylactic and therapeutic), antiplatelet therapy, and PICC use significantly lowered the risk of CRT. The findings support personalized prevention strategies and underscore the need for a well-designed randomized controlled trial to validate these findings.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization II: Right Heart Catheterization
Urinary Tract Infection II: Pathophysiology

